Andy Cohen TRT: What Clinicians Should Tell Patients

Why Andy Cohen's TRT Disclosure Matters Clinically

Andy Cohen's willingness to discuss hormone therapy publicly has measurable downstream effects in clinical practice. Male patients who historically avoided conversations about low energy, low libido, or mood changes now arrive with a specific question: "Can I get what Andy Cohen is on?" That shift in patient-initiated dialogue is worth taking seriously. It does not mean every patient qualifies, but it does mean the exam room conversation has already started before the patient sits down.

The Celebrity Disclosure Effect on Patient Behavior

Patients routinely cite public figures when discussing treatments they have researched. A 2019 analysis published in the Journal of General Internal Medicine found that celebrity health disclosures were associated with measurable changes in health-seeking behavior among audiences [1]. TRT is not an exception. Cohen's disclosure, made in multiple media appearances including his podcast "Andy Cohen Live," positions testosterone therapy as normalized and accessible, which can be both helpful and misleading depending on the individual patient's clinical picture.

What Cohen Has Actually Said

Cohen has described using testosterone therapy to address fatigue and general aging-related changes. He has not specified a diagnosis of clinical hypogonadism in publicly available statements. Clinicians should label this clearly when patients bring it up: Cohen's personal experience is anecdote, not clinical data. The Endocrine Society's 2018 Clinical Practice Guideline on testosterone therapy states directly that treatment should be offered "to men who have both low serum testosterone levels and symptoms of hypogonadism" [2]. Anecdote does not substitute for that two-part criterion.

The Diagnostic Standard for Male Hypogonadism

The diagnostic bar for TRT is specific. Patients citing celebrity use often underestimate what is required before a clinician should prescribe.

Biochemical Confirmation Comes First

The Endocrine Society and the American Urological Association both require at least two morning total testosterone measurements below 300 ng/dL on separate occasions before a diagnosis of hypogonadism is made [2][3]. A single low reading is not sufficient. Testing should occur between 7 a.m. And 10 a.m., when testosterone peaks naturally. Results drawn in the afternoon can underestimate true levels by 20 to 25% due to diurnal variation [4].

Symptoms Alone Are Not Enough

The classic symptom triad of fatigue, reduced libido, and decreased morning erections overlaps with depression, sleep apnea, thyroid dysfunction, and anemia. The AUA's 2018 guideline specifically cautions against treating symptoms without biochemical confirmation [3]. A patient who says "I feel like Andy Cohen describes" deserves a thorough workup, not a prescription.

Secondary Hypogonadism Requires Additional Steps

When low testosterone is confirmed, the next step is determining whether the origin is primary (testicular failure, elevated LH and FSH) or secondary (pituitary or hypothalamic, with low or normal LH and FSH). Secondary hypogonadism warrants pituitary MRI if prolactin is elevated or if the clinical picture suggests a structural lesion [2]. Skipping this step misses treatable causes like hyperprolactinemia or hemochromatosis.

What the Evidence Actually Shows About TRT Benefits

Patients citing Cohen's self-reported improvements want to know whether those benefits are real and reproducible. The answer is: some are, within a specific population.

Sexual Function and Libido

The Testosterone Trials (TTrials), a coordinated set of seven placebo-controlled trials in men 65 and older with confirmed hypogonadism (N=788 in the sexual function sub-trial), showed statistically significant improvements in sexual desire and erectile function with testosterone gel titrated to mid-normal range [5]. The effect was modest but consistent. The TTrials investigators reported a mean increase of 1.3 points on the Psychosexual Daily Questionnaire sexual desire score (P<0.001) compared to placebo [5].

Energy and Mood

The same TTrials cohort showed a small but statistically significant improvement in self-reported vitality in the Physical Function Trial, though improvements in objective walking distance did not reach significance in all arms [6]. Patients should understand that "feeling better" is a real outcome for some men with confirmed hypogonadism, but the magnitude is often smaller than celebrity accounts suggest.

Body Composition

TRT consistently reduces fat mass and increases lean mass in hypogonadal men. A meta-analysis of 58 randomized controlled trials (N=3,867) published in the Journal of Clinical Endocrinology and Metabolism found that testosterone therapy reduced fat mass by a mean of 1.6 kg and increased lean mass by a mean of 1.6 kg over 12 to 24 months [7]. These are real changes, but they are not dramatic transformations without concurrent dietary and exercise intervention.

Cardiovascular Safety: The TRAVERSE Trial

The cardiovascular safety question dominated TRT discussions for a decade after the 2010 Basaria trial was stopped early due to excess cardiovascular events [8]. Clinicians need to be current on this, because patients will ask.

TRAVERSE Design and Results

The TRAVERSE trial (N=5,246; mean age 65.8 years; follow-up 33 months) was a randomized, double-blind, placebo-controlled trial specifically designed to assess cardiovascular safety of testosterone gel 1.62% in men with hypogonadism and either established or high risk of cardiovascular disease [9]. The primary outcome was major adverse cardiovascular events (MACE: nonfatal MI, nonfatal stroke, or cardiovascular death).

TRAVERSE found no significant difference in MACE between testosterone (7.0%) and placebo (7.3%), with a hazard ratio of 0.96 (95% CI 0.78 to 1.17) [9]. The FDA reviewed these data and updated the TRT label in 2023 to remove the broad cardiovascular warning box for men with confirmed hypogonadism, though the label retains a warning for cardiovascular risk in general [10].

Atrial Fibrillation Signal

TRAVERSE did identify a higher rate of atrial fibrillation in the testosterone arm (3.5% vs. 2.4%; P<0.001) [9]. This finding is clinically meaningful. Patients with existing AF or significant AF risk factors should be counseled about this before initiating therapy.

Pulmonary Embolism Signal

Venous thromboembolism events, including pulmonary embolism, occurred at a numerically higher rate in the testosterone arm of TRAVERSE [9]. The FDA label for testosterone products carries a warning for VTE risk [10]. Patients with personal or family history of clotting disorders require pre-treatment workup including thrombophilia screening.

Fertility and Spermatogenesis

This is the counseling point most likely to be omitted in a brief clinical encounter, and it is the one most likely to produce downstream patient regret.

Suppression of the HPG Axis

Exogenous testosterone suppresses the hypothalamic-pituitary-gonadal axis. Gonadotropin levels (LH and FSH) fall, intratesticular testosterone drops dramatically, and spermatogenesis is suppressed. Azoospermia can develop within three to four months of TRT initiation [11]. Recovery after cessation is not guaranteed, particularly after prolonged use.

Alternatives for Men Wanting to Preserve Fertility

Men who desire future fertility should be offered alternatives before TRT is started. Clomiphene citrate (25 to 50 mg every other day) stimulates endogenous LH and FSH release, raises intratesticular testosterone, and preserves spermatogenesis [12]. Human chorionic gonadotropin (hCG) can be added to TRT protocols or used alone to maintain spermatogenesis during therapy [11]. Sperm banking before TRT initiation is the most reliable option and should be offered explicitly.

Monitoring Protocol After TRT Initiation

Once therapy begins, monitoring is not optional. The Endocrine Society specifies a structured follow-up schedule [2].

Three-Month Assessment

At three months, measure total testosterone (target mid-normal range, approximately 400 to 700 ng/dL), hematocrit (withhold or reduce dose if above 54%), and PSA. Review symptom response. Adjust formulation or dose based on levels and patient-reported outcomes.

Ongoing Surveillance

After the three-month check, repeat testosterone, hematocrit, and PSA at 12 months, then annually. Digital rectal exam annually for men over 40. Bone density assessment (DEXA) at baseline and every one to two years for men with osteoporosis. Patients should know the monitoring schedule before they start, not after.

Hematocrit Management

Polycythemia is the most common laboratory abnormality during TRT. Hematocrit rising above 54% requires dose reduction, formulation change (injectable preparations produce higher peak levels than gels), or temporary cessation [2]. Phlebotomy may be used in persistent cases, though dose adjustment is the preferred first step.

Formulation Choices and What Patients Ask About

Patients who have read about Cohen's TRT or celebrity protocols often arrive with specific formulations in mind. A brief clinical summary helps clinicians redirect that conversation toward individualized selection.

Topical Gels and Creams

Testosterone gel 1% and 1.62% (AndroGel, Testim, Vogelxo) and compounded creams provide stable serum levels with low peak-to-trough variation. Transfer to partners or children through skin contact is a real risk and requires counseling [10]. Application to clean, dry skin followed by handwashing and covering the area reduces transfer risk.

Injectable Testosterone

Testosterone cypionate and testosterone enanthate (50 to 200 mg IM every one to two weeks) are low-cost and widely available. They produce higher peak levels shortly after injection and lower trough levels before the next dose, which some patients experience as mood variability. Testosterone undecanoate (Aveed) given every 10 weeks after two loading doses produces more stable levels but carries a rare risk of pulmonary oil microembolism requiring a 30-minute observation period post-injection [10].

Subcutaneous Pellets

Testosterone pellets (Testopel) are implanted subcutaneously every three to six months. Levels are stable but not adjustable once implanted. Pellet extrusion occurs in approximately 5 to 10% of insertions [13]. Clinicians using pellets need a clear protocol for managing inadequate or excessive response.

Nasal and Buccal Options

Testosterone nasal gel (Natesto) is applied three times daily and produces lower DHT levels, which may be advantageous for men concerned about hair loss or prostate effects [14]. Buccal testosterone (Striant) is applied twice daily but has a high rate of gum and mouth irritation leading to discontinuation [14].

Absolute and Relative Contraindications

Not every patient who asks deserves a prescription. Clinicians must screen for contraindications before initiation.

Absolute Contraindications

TRT is absolutely contraindicated in men with prostate cancer (current or suspected), breast cancer, hematocrit above 54% at baseline, untreated severe obstructive sleep apnea, and a desire for fertility in the near term [2][3]. These are not negotiable regardless of symptom burden or celebrity precedent.

Relative Contraindications

Relative contraindications include PSA above 4 ng/mL without prior urology evaluation, PSA velocity above 1.4 ng/mL per year, controlled heart failure with reduced ejection fraction, and untreated polycythemia vera [2]. These require shared decision-making and, in many cases, specialist input before proceeding.

How to Frame the Conversation When a Patient Mentions Andy Cohen

When a patient opens with "I heard Andy Cohen does TRT and I want to try it," the clinical response should follow a structured path rather than reacting to the celebrity framing.

Step 1. Acknowledge without amplifying. Say: "Cohen has talked about this publicly, and it's brought a lot of men into conversations they might have avoided. Let's figure out whether this actually applies to you."

Step 2. Order the right labs before discussing treatment. Two morning total testosterone levels, LH, FSH, prolactin, CBC, PSA, and a metabolic panel. Do not prescribe based on symptoms alone.

Step 3. Use the data to anchor the discussion. The American Urological Association guideline is explicit: "We recommend against the use of testosterone therapy for men with symptoms alone in the absence of biochemical hypogonadism." [3] Share that sentence with the patient.

Step 4. Discuss the full benefit-to-risk profile honestly. Sexual function and lean mass improvements are real but modest. The atrial fibrillation signal from TRAVERSE is real. Fertility suppression is real. The patient deserves all three data points, not just the appealing ones.

Step 5. Set a monitoring plan before writing the first prescription. Patients who understand the monitoring schedule are more likely to return for follow-up and less likely to self-adjust doses based on influencer content.

Addressing the "Optimization" Framing

Many patients influenced by celebrity TRT discourse arrive using the language of optimization rather than disease treatment. They describe testosterone therapy as "getting my levels to where they should be" or "performing at my best." This framing is worth addressing directly.

The FDA has not approved testosterone therapy for age-related decline in testosterone levels (sometimes called late-onset hypogonadism or "andropause") as a standalone indication. The approved indication is hypogonadism with both biochemical and clinical criteria met [10]. A 58-year-old man with a testosterone of 340 ng/dL and no symptoms does not meet the clinical threshold for treatment under current guidelines, regardless of what a podcast host describes.

The AACE/ACE 2022 guidelines on male hypogonadism state: "Testosterone therapy should not be initiated in patients with testosterone levels in the normal reference range, even if they report symptoms." [15] This sentence is worth having ready in the exam room.